EyePoint Pharmaceuticals, Inc. (EYPT): Price and Financial Metrics


EyePoint Pharmaceuticals, Inc. (EYPT): $7.83

0.01 (+0.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EYPT POWR Grades


  • Value is the dimension where EYPT ranks best; there it ranks ahead of 58.51% of US stocks.
  • EYPT's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
  • EYPT ranks lowest in Momentum; there it ranks in the 12th percentile.

EYPT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for EYPT is 0.2 -- better than merely 16.96% of US stocks.
  • EYPT's price/sales ratio is 11.59; that's higher than the P/S ratio of 87.38% of US stocks.
  • EyePoint Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -50.68%, greater than the shareholder yield of only 8.81% of stocks in our set.
  • Stocks that are quantitatively similar to EYPT, based on their financial statements, market capitalization, and price volatility, are QMCO, SCWX, CLPT, LKCO, and NURO.
  • EYPT's SEC filings can be seen here. And to visit EyePoint Pharmaceuticals Inc's official web site, go to eyepointpharma.com.

EYPT Valuation Summary

  • In comparison to the median Healthcare stock, EYPT's price/earnings ratio is 120.82% lower, now standing at -7.6.
  • Over the past 202 months, EYPT's price/sales ratio has gone down 1296.
  • Over the past 202 months, EYPT's price/sales ratio has gone down 1296.

Below are key valuation metrics over time for EYPT.

Stock Date P/S P/B P/E EV/EBIT
EYPT 2021-08-31 8.0 2.9 -7.6 -6.4
EYPT 2021-08-30 7.4 2.7 -7.0 -5.7
EYPT 2021-08-27 7.4 2.7 -7.0 -5.7
EYPT 2021-08-26 7.3 2.7 -6.9 -5.6
EYPT 2021-08-25 7.3 2.7 -6.9 -5.6
EYPT 2021-08-24 7.4 2.7 -7.0 -5.7

EYPT Growth Metrics

    The 5 year price growth rate now stands at -69.77%.
  • Its 2 year price growth rate is now at -56.62%.
  • Its year over year price growth rate is now at 25.06%.
EYPT's revenue has moved up $31,284,000 over the prior 34 months.

The table below shows EYPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 36.939 -50.097 -58.417
2021-09-30 32.526 -27.534 -54.454
2021-06-30 39.162 -18.611 -41.56
2021-03-31 34.271 -13.189 -44.5
2020-12-31 34.437 -14.435 -45.394
2020-09-30 35.939 -31.816 -40.335

EYPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EYPT has a Quality Grade of C, ranking ahead of 30.89% of graded US stocks.
  • EYPT's asset turnover comes in at 0.293 -- ranking 58th of 75 Measuring and Control Equipment stocks.
  • BRKR, HURC, and ONTO are the stocks whose asset turnover ratios are most correlated with EYPT.

The table below shows EYPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.293 0.804 -0.673
2021-03-31 0.322 0.818 -0.674
2020-12-31 0.433 0.831 -0.636
2020-09-30 0.480 0.870 -0.520
2020-06-30 0.301 0.862 -0.717
2020-03-31 0.319 0.871 -0.715

EYPT Price Target

For more insight on analysts targets of EYPT, see our EYPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.20 Average Broker Recommendation 1.4 (Strong Buy)

EYPT Stock Price Chart Interactive Chart >

Price chart for EYPT

EYPT Price/Volume Stats

Current price $7.83 52-week high $21.50
Prev. close $7.82 52-week low $6.99
Day low $7.56 Volume 97,200
Day high $7.97 Avg. volume 183,848
50-day MA $9.63 Dividend yield N/A
200-day MA $11.48 Market Cap 266.59M

EyePoint Pharmaceuticals, Inc. (EYPT) Company Bio


EyePoint Pharmaceuticals (formerly pSivida Corp.) develops sustained-release drug-delivery products for treating eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company was founded in 1987 and is based in Watertown, Massachusetts.


EYPT Latest News Stream


Event/Time News Detail
Loading, please wait...

EYPT Latest Social Stream


Loading social stream, please wait...

View Full EYPT Social Stream

Latest EYPT News From Around the Web

Below are the latest news stories about EyePoint Pharmaceuticals Inc that investors may wish to consider to help them evaluate EYPT as an investment opportunity.

Myriad Genetics (MYGN) Reports Q4 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and highlight recent corporate developments. To access the live conference call, plea

Yahoo | February 24, 2022

EyePoint Pharmaceuticals reports positive data EYP-1901 data for the treatment of wet AMD

EyePoint Pharmaceuticals (NASDAQ:EYPT) announces eight-month interim data from the DAVIO Phase 1 clinical trial of EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD). The data will be presented at the  Angiogenesis, Exudation, and Degeneration 2022 virtual meeting. Eight--month interim data from the Phase 1 DAVIO clinical trial show no reports of ocular serious...

Seeking Alpha | February 14, 2022

EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Could Slash -550.0% Soon

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) price on Friday, February 11, rose 1.11% above its previous days close as an upside momentum from buyers pushed the stocks value to $10.00. A look at the stocks price movement, the close in the last trading session was $9.89, moving within a range at $9.48 and $10.19. The beta value EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Could Slash -550.0% Soon Read More »

Stocks Register | February 12, 2022

EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

WATERTOWN, Mass., Feb. 12, 2022 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced updated interim data from the

PR Newswire | February 12, 2022

Read More 'EYPT' Stories Here

EYPT Price Returns

1-mo -18.86%
3-mo -35.56%
6-mo -36.03%
1-year -12.90%
3-year -54.21%
5-year -54.21%
YTD -36.03%
2021 86.02%
2020 -57.55%
2019 -17.99%
2018 75.00%
2017 -36.84%

Continue Researching EYPT

Here are a few links from around the web to help you further your research on EyePoint Pharmaceuticals Inc's stock as an investment opportunity:

EyePoint Pharmaceuticals Inc (EYPT) Stock Price | Nasdaq
EyePoint Pharmaceuticals Inc (EYPT) Stock Quote, History and News - Yahoo Finance
EyePoint Pharmaceuticals Inc (EYPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4753 seconds.